{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:36:27Z","timestamp":1792305387208,"version":"4.4.0"},"reference-count":22,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"abstract":"<jats:p>Cancer stem cells (CSC) are a potential cause for recurrence, metastasis, and resistance of tumors to different therapeutic modalities like hormonal radiotherapy and chemotherapy. We investigated two CSC markers (NANOG and CD 133) in normal, hyperplastic endometrium and endometrial carcinoma. A total of 93 formalin-fixed paraffin-embedded tissue blocks were used for immunohistochemical expression of NANOG and CD133 markers. NANOG expression was detected in 88.37% of endometrial carcinoma cases compared to 15% of the normal proliferative endometrium and 60% of hyperplasia cases. In endometrial carcinoma, high NANOG expression was significantly correlated with high grade, deep myometrial invasion, lymph node metastasis, and high stage with p-values (0.009, 0.005, 0.014, and 0.003, respectively). CD133 was positive in 76.74% of endometrial carcinoma cases, and it showed a significant correlation with deep myometrial invasion, positive lymph node, positive lymphovascular invasion, and high stage (p-values 0.003, 0.001, 0.003, and 0.013, respectively). Normal endometrium showed less expression of CD133 (only 5%) than hyperplasia and endometrial carcinoma with a statistically highly significant difference (p less than 0.0001). Hyperplastic cases with atypia expressed higher CD133 than those without atypia (6 out of 12 versus 3 out of 18). However, this difference was not statistically significant (p-value 0.111). The cancer stem cell markers NANOG and CD 133 are expressed in a high percentage in endometrial carcinoma compared to normal and hyperplasia and their expression is positively correlated with the aggressive behavior of the tumor. High expression of these two markers in apparently normal tissue around the tumor and in hyperplastic conditions with atypia suggests the possibility to use NANOG and CD133 expression as a diagnostic marker distinguishing dysplasia from reactive atypia. Therefore, inhibition of these markers can be a promising method to stop the progression of early cancers.<\/jats:p>","DOI":"10.25122\/jml-2021-0206","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T11:35:27Z","timestamp":1668771327000},"page":"117-123","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium"],"prefix":"10.25122","volume":"15","author":[{"given":"Methaq","family":"Al-Kaabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pathology and Forensic Medicine Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Methaq Al-Kaabi, Pathology and Forensic Medicine Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq. E-mail: Abdullah.anishm@gmail.com","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalida","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Anatomy, Histology and Embryology Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdal-jabbar","family":"Al-Rubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Anatomy, Histology and Embryology Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Zhang S, Gong T, Liu F, Jiang Y, et al. Global, Regional, and National Burden of Endometrial Cancer, 1990\u20132017: Results From the Global Burden of Disease Study. Frontiers in Oncology 2019; 9: 1440. doi: 10.3389\/fonc.2019.01440.","DOI":"10.3389\/fonc.2019.01440"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L. Global Cancer Statistics GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2018; 68:394\u201342. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21492"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Castell\u00f3n E, Valenzuela R, Lillo J, Castillo V, et al. Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. Biol. Res. 2012; 45 (3): 297-305. doi: 10.4067\/S0716-97602012000300011.","DOI":"10.4067\/S0716-97602012000300011"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Zhu P, Fan Z. Cancer stem cells and tumorigenesis. Biophys Rep. 2018; 4(4):178\u2013188. doi: 10.1007\/s41048-018-0062-2.","DOI":"10.1007\/s41048-018-0062-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Grubelnik G, Bostjancic E, Pavlic A, Kos M, Zidar N. NANOG expression in human development and cancerogenesis. Experimental Biology and Medicine 2020; 245(5): 1\u20139. doi: 10.1177\/1535370220905560.","DOI":"10.1177\/1535370220905560"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Henderson T, Chen M, Darrow MA, Li CS, et al. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft tissue sarcomas. J Surg Res. 2018; 223:207\u2013214. doi: 10.1016\/j.jss.2017.11.016.","DOI":"10.1016\/j.jss.2017.11.016"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Saravi O, Naghshvar F, Torabizadeh Z, Sheidaei S. Immunohistochemical Expression of Nanog and its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma. Iranian Biomedical Journal. 2019; 23 (3): 184-189. doi: 10.29252\/.23.3.184.","DOI":"10.29252\/ibj.23.3.184"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Gong S, Li Q, Jeter CR, Fan Q, et al. Regulation of NANOG in cancer cells. Mol Carcinog 2015; 54:679\u201387. doi: 10.1002\/mc.22340.","DOI":"10.1002\/mc.22340"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. de Vicente JC, Rodriguez T, Rodrigo JP, Allonca E, et al. The emerging role of NANOG as an early cancer risk biomarker in patients with oral potentially malignant disorders. J Clin Med. 2019; 8:1376. doi: 10.3390\/jcm8091376.","DOI":"10.3390\/jcm8091376"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Glumac P, Le Beau A. The role of CD133 in cancer: a concise review. Clin Transl Med 2018; 7(1):18. doi: 10.1186\/s40169-018-0198-1.","DOI":"10.1186\/s40169-018-0198-1"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res.2008; 68(19):7882\u20137886. doi: 10.1158\/0008-5472.CAN-08-0723.","DOI":"10.1158\/0008-5472.CAN-08-0723"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Elbasateeny S, Salema A, Abdelsalam W, Salem R. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathology \u2013 Research and Practice 2016; 212:10\u201316. doi: 10.1016\/j.prp.2015.10.008.","DOI":"10.1016\/j.prp.2015.10.008"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Science 2011; 102(4): 903\u2013908. doi: 10.1111\/j.1349-7006.2011.01864.x.","DOI":"10.1111\/j.1349-7006.2011.01864.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Roudi R, Barodabi M, Madjd Z, Roviello G, et al. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. Molecular & Cellular Oncology 2020; 7(5): doi: 10.1080\/23723556.2020.1788366.","DOI":"10.1080\/23723556.2020.1788366"},{"key":"#cr-split#-ref15.1","doi-asserted-by":"crossref","unstructured":"15. Giannone G, Attademo L, Scotto G, Genta S, et al. Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. Cancers 2019","DOI":"10.3390\/cancers11111820"},{"key":"#cr-split#-ref15.2","doi-asserted-by":"crossref","unstructured":"11: 1820. doi: 10.3390\/cancers11111820.","DOI":"10.3390\/cancers11111820"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Zhao L, Liu J, Chen S, Fang C, et al. Prognostic significance of NANOG expression in solid tumors: a meta-analysis. Onco Targets Ther. 2018; 11: 5515\u20135526. doi: 10.2147\/OTT.S169593.","DOI":"10.2147\/OTT.S169593"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Shorky, Nihal H, Mohmoud, Abdel N, Hamid MH. Immunohistochemical expression of stem cell markers CD133 and Oct-4 in cases of endometrial hyperplasia and endometrial carcinoma. Egyptian Journal of Pathology 2017; 37: 154-159. doi :10.1097\/01.XEJ.0000516731.35034.c8.","DOI":"10.1097\/01.XEJ.0000516731.35034.c8"},{"key":"ref18","unstructured":"18. Lu G, Zhou L, Song W, Wu S, et al. Expression of ORAOV1, CD133 and WWOX correlate with metastasis and prognosis in gastric adenocarcinoma. Int J Clin Exp Pathol. 2017; 10(8): 8916\u20138924."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Fathi A, Mosaad H, Hussein S, Roshdy M, Ismail E. Prognostic significance of CD133 and ezrin expression in colorectal carcinoma. IUBMB life 2017; 69(5): 328-340. doi: 10.1002\/iub.1609.","DOI":"10.1002\/iub.1609"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Yalan Bi, Meng Y, Wu H, Cui Q. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis. J Surg Oncol. 2016; 113(2):144-51. doi: 10.1002\/jso.24124.","DOI":"10.1002\/jso.24124"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98; 1389-97. doi: 10.1038\/sj.bjc.6604307.","DOI":"10.1038\/sj.bjc.6604307"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/JMedLife-15-117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T11:35:35Z","timestamp":1668771335000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/JMedLife-15-117.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["JMedLife-15-117"],"URL":"https:\/\/doi.org\/10.25122\/jml-2021-0206","relation":{},"ISSN":["1844-122X","1844-3117"],"issn-type":[{"value":"1844-122X","type":"print"},{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}